Supply of Fully Automated HPLC Dissolution System

The contract calls for the procurement, delivery, and installation of a commercial off-the-shelf fully automated HPLC dissolution system designed for pharmaceutical testing under GDUFA guidelines. The system must meet strict regulatory and performance standards to support FDA-required analytical workflows, ensuring accurate, reproducible, and compliant dissolution data for drug product evaluation. Delivery and installation are to occur at the specified place of performance in Silver Spring, Maryland, with the system expected to be fully operational and calibrated upon completion. The contract is structured as a subcontract under the Department of Health and Human Services, specifically managed by the FDA Office of Acquisition and Grant Services, and is classified under NAICS code 334516 for analytical laboratory equipment manufacturing. All proposed solutions must conform to current good manufacturing and laboratory practices without customization or development of proprietary hardware or software. Responses to this solicitation are due by July 20, 2026, with the opportunity publicly posted on July 9, 2026. The procurement is aimed at modernizing dissolution testing infrastructure to enhance efficiency and data integrity across pharmaceutical quality control processes. No set-aside provisions apply, and the contract does not specify a point of contact, indicating that all inquiries must follow standard federal solicitation protocols. The system must integrate seamlessly into existing laboratory environments and support regulatory reporting requirements under U.S. pharmaceutical oversight. While no details are provided regarding warranty, training, or maintenance, these are implied as essential components for compliance and long-term functionality.